ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen LLC, a biotechnology company developing proprietary gene-based molecular diagnostics announced today the closing of a $300,000 investment from Delaware Crossing Investor Group, a Mid-Atlantic region angel investor group. The funds will be used to help SensiGen accelerate development and commercialization of the Company’s revolutionary AttoSense™ molecular diagnostic technology.
